Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit T cell-mediated cytotoxicity by inhibiting Fas ligand expression

Journal of Immunology

Volumn 165, Issue 1, 2000, Pages 114-123

  Delgado, Mario ^a,b   Ganea, Doina ^a  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; GRANZYME A; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; LIGAND; NEUROPEPTIDE; PERFORIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ARTICLE; CELL ACTIVITY; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DOWN REGULATION; EFFECTOR CELL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034235796     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.165.1.114     Document Type: Article

References (53)

1. Berke, G. 1995. The CTL kiss of death. Cell 81:9.
2. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science 267:1449.
3. Shiver, J. W., L. Su, and P. A. Henkart. 1992. Cytotoxicity with target DNA breakdown by rat basophilic leukemia cells expressing both cytolysin and granzyme A. Cell 71:315.
4. 2+-independenl T cell-mediated cytotoxicity. J. Exp. Med. 177:195.
5. Kagi, D., F. Vignaux, B. Ledermann, K. Burki, V. Depraetere, S. Nagata, H. Hengartner, and P. Golstein. 1994. Fas and perform pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528.
6. Walsh, C. M., A. A. Glass, V. Chiu, and W. R. Clark. 1994. The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J. Immunol. 153:2506.
7. Takahashi, T., M. Tanaka, C. I. Brannan, N. A. Jenkins, N. G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice caused by a point mutation, in the Fas ligand. Cell 76:969.
8. +cytotoxic cells. Proc. Natl. Acad. Sci. USA 91:4185.
9. + T cell-mediated cytotoxicity. J. Immunol. 152:1127.
10. Vignaux, F., and P. Golstein. 1994. Fas-based lymphocyte-mediated cytotoxicity against syngeneic activated lymphocytes: a regulatory pathway. Eur. J. Immunol. 24:923.
11. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R. C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377:630.
12. Bellinger, D. L., D. Lorton, S. Brouxhon, S. Felten, and D. L. Felten. 1996. The significance of vasoactive intestinal peptide (VIP) in immunomodulation. Adv. Neuroimmunol. 6:5.
13. Ganea, D. 1996. Regulatory effects of vasoactive intestinal peplide on cytokine production in central and peripheral lymphoid organs. Adv. Neuroimmunol. 6:61.
14. De la Fuente, M., M. Delgado, and R. P. Gomariz. 1996. VIP modulation of immune cell functions. Adv. Neuroimmunol. 6:75.
15. Pozo, D., M. Delgado, C. Martinez, J. Leceta, R. P. Gomariz, J. M. Guerrero, and J. R. Calvo. 2000. Immunobiology of VIP. Immunol. Today 21:7.
16. Delgado, M., E. J. Munoz-Elias, C. Martinez, R. P. Gomariz, and D. Ganea. 1999, Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP38) modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines. Ann. NY Acad. Sci. 897:401.
17. Delgado, M., and D. Ganea. 2000. VIP and PACAP inhibit antigen-induced apoptosis in mature T lymphocytes by inhibiting FasL expression. J. Immunol. 164:1200.
18. 2+ in Fas ligand-induced lysis. J. Immunol. 159:3140.
19. Carter, L. L., and R. W. Dutton. 1995. Relative perform- and Fas-mediated lysis in T1 and T2 CDS effector populations. J. Immunol. 155:1028.
20. Carter, L. L., and R. W. Dutton. 1996. Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr. Opin. Immunol. 8:336.
21. Berke, G., K. A. Sullivan, and D. B. Amos. 1972, Rejection of ascites tumor allografts. I. Isolation, characterization and in vitro reactivity of peritoneal lymphoid effector cells from BALB/c mice immune to EL4 leukosis. J. Exp. Med. 135:1334.
22. Zheng, L., C. L. Trageser, D. M. Willerford, and M. J. Lenardo. 1998. T cell growth cytokines cause the superinduction of molecules mediating antigen-induced T lymphocyte death. J. Immunol. 160:763.
23. Delgado, M., E. J. Munoz-Elias, Y. Kan, I. Gozes, M. Fridkin, D. E. Brenneman, R. P. Gomariz, and D. Ganea. 1998. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit TNFα transcriptional activation by regulating NF-κB and CREB/c-Jun. J. Biol. Chem. 273:31436.
24. Stunner, T., R. J. Mogil, D. LaFace, N. J. Yoo, A. Mahboubi, F. Echevarri, S. J. Marin, W. R. Force, D. H. Lynch, C. F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature 373:441.
25. Fitzpatrick, L., A. P. Makrigiannis, M. Kaiser, and D. W. Hoskin. 1996. Anti-CD3-activated killer T cells: interferon-y and interleukin-10 cross-regulate granzyme B expression and the induction of major histocompatibility complex-unrestricted cytotoxicity. J. Interferon Cytokine Res. 16:537.
26. Makrigiannis, A. P., and D. W. Hoskin. 1997. Inhibition of CTL induction by rapamycin: IL-2 rescues granzyme B and perform expression but only partially restores cytotoxic activity. J. Immunol. 159:4700.
27. Itoh, N., S. Yonehara, A. Ishii, M. Yonehara, S. I. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233.
28. Hartnar, A. J., A. Arimura, I. Gozes, L. Journot, M. Laburthe, J. R. Pisegna, S. R. Rawlings, P. Robberecht, S. I. Said, S. P. Sreedharan, et al. 1998. Nomenclature of receptors for vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP). Pharmacol. Rev. 50:625.
29. Delgado, M., C. Martinez, M. J. Johnson, R. P. Gomariz, and D. Ganea. 1996. Differential expression of vasoactive intestinal peptide receptors 1 and 2 (VIP-R1 and VIP-R2) mRNA in murine lymphocytes. J. Neuroimmunol. 68:27.
30. Jiang, X., H.-Y. Wang, J. Yu, and D. Ganea. 1998. VIP1 and VIP2 receptors but not PVR1 mediate the effect of VIP/PACAP on cytokine production in T lymphocytes. Ann. NY Acad. Sci. 865:397.
31. Gourlet, P., A. Vandermeers, P. Vertongen, J. Ratche, P. De Neef, J. Cnudde, M. Waelbroeck, and P. Robberecht. 1997. Development of high affinity selective VIP1 receptor agonists. Peptides 18:1539.
32. Xia, M., S. P. Sreedharan, D. R. Bolin, G. O. Gaufo, and E. J. Goetzl. 1997. Novel cyclic peptide agonist of high potency and selectivity for the lype II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281:629.
33. Moro, O., and E. A. Lerner. 1996. Maxadilan, the vasodilator peptide from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J. Biol. Chem. 271:966
34. Croft, M., L. Carter, S. L. Swain, and R. W. Dutton. 1994. Generation of polarized antigen-specific CD8 effector populations: reciprocal action of IL-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180:2401.
35. + T cell clones can provide B cell help. J. Immunol. 154:3118.
36. + T cells secreting Th1 or Th2 cytokines. Immunity 2:271.
37. Berke, G. 1994. The binding and lysis of target cells by cytotoxic lymphocytes: molecular and cellular aspects. Annu. Rev. Immunol. 12:735.
38. Kojima, H., N. Shinohara, S. Hanaoka, Y. Someya-Shirota, Y. Takagaki, H. Ohno, T. Saito, T. Katayama, H. Yagita, K. Okumura, et al. 1994. Two distinct pathways of specific killing revealed by perform mutant cytotoxic T lymphocytes. Immunity 1:357.
39. Ostergaard, H., and W. R. Clark. 1989. Evidence for multiple lytic pathways used by cytotoxic T lymphocytes. J. Immunol. 143:2120.
40. Trenn, G., H. Takayama, and M. Sitkovsky. 1987. Exocytosis of cytolytic granules may not be required for target cell lysis by cytotoxic T-lymphocytes. Nature 330:72.
41. Glass, A., C. M. Walsh, D. H. Lynch, and W. R. Clark. 1996. Regulation of the Fas lytic pathway in cloned CTL. J. Immunol. 156:3638.
42. Li, J., D. Rosen, D. Ronen, C. K. Dehrens, P. H. Krammer, W. R. Clark, and G. Berke. 1998. The regulation of CD95 ligand expression and function in CTL. J. Immunol. 161:3943.
43. Clark, W. R., C. M. Walsh, A. A. Glass, F. Hayashi, M. Matloubian, and R. Ahmed. 1995. Molecular pathways of CTL-mediated cytotoxicity. Immunol. Rev. 146:33.
44. Lowin, B., C. Mattman, M. Hahne, and J. Jschopp. 1996. Comparison of Fas (Apo-1/CD95)- and perforin-medialed cytotoxicity in primary T lymphocytes. Int. Immunol. 8:57.
45. + cells. J. Exp. Med. 186:1407.
46. Van Parijs, L., Y. Refaeli, J. D. Lord, B. H. Nelson, A. K. Abbas, and D. Baltimore. 1999. Uncoupling IL-2 signals lhat regulate T cell proliferation, survival, and Fas-mediated activation-induced cell death. Immunity 11:281.
47. + T cell death. J. Immunol. 163:3131.
48. Hadida, F., V. Vieillard, L. Mollet, I. dark-Lewis, M. Baggiolini, and P. Debre. 1999. Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells. J. Immunol. 163:1105.
49. Kaser, A., S. Nagata, and H. Tilg. 1999. Interferon α augments activation-induced T cell death by upregulation of Fas and Fas ligand expression. Cytokine 11:736.
50. Smyth, M. J. 1997. Fas ligand-mediated bystander lysis of syngeneic cells in response to an allogeneic stimulus. J. Immunol. 158:5765.
51. + T helper 1 effector. J. Immunol. 157:2961.
52. Suhrbier, A., S. R. Burrows, A. Fernan, M. F. Lavin, G. D. Baxter, and D. J. Moss. 1993. Peptide epitope induced apoptosis of human cytotoxic T lymphocytes: implications for peripheral T cell deletion and peptide vaccination. J. Immunol. 150:2169.
53. De Maria, R., and R. Testi. 1998. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol. Today 19:121.